Dysregulation of Ndc80-NUF2 has been employed in the development of a series of human cancers, including lung cancer, colorectal cancer, gastric cancer, prostate cancer, urinary bladder cancer, renal carcinoma and ovarian cancer, rather than other normal tissues except testis [13–18]. This evidence concerns the gene NUF2 and prostate carcinoma.